In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Disruption in healthcare will be driven by the power of its trapped – and highly exploitable – value.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

While the Graham-Cassidy bill failed to come to a vote keeping ACA as the law of the land, changes are coming. Here are four ways to react.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Healthcare organizations are working hard to become consumer-centric. To achieve real success, they need to focus on becoming magnetic.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Insights in your inbox

Subscribe

Terry Stone writes in The Hill on the critical need to partner with American businesses during this next phase of health reform.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman
Senior Partner, Healthcare Reform Leader, Mercer

Even amidst the uncertainty of repeal and replace, we see some meaningful trends taking shape. Read our predictions for 2017.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman
Head of Health & Life Sciences, North America, Oliver Wyman

Trendspotting in unpredictable times. This infographic highlights five predictions for 2017.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman
Head of Health & Life Sciences, North America, Oliver Wyman

Terry Stone on the need to push harder on initiatives that put focus on value, outcomes, and experience.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

What prevents companies from breaking through the consumer hassle map? Too much time fixing broken bits and not enough time fundamentally rethinking root-cause issues.

Managing Partner, Health & Life Sciences, and Global Chair for I&D, Oliver Wyman

Insights in your inbox

Subscribe
Load More